Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FGFR3::TACC3 status confers therapeutic sensitivity to Erdafitinib in patients with Bladder Urothelial Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.